Harbour BioMed inks $350 million deal for rights to A167
Member News
USA-based Harbour BioMed has entered into an exclusive strategic partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167
Related or similar articles
August 19, 2019
Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Member News
.webp)
April 29, 2024
Lab Space Boston: Navigating Opportunities and Challenges
Hello, fellow science enthusiasts! If you're on the hunt for the perfect laboratory space in greater Boston and Cambridge, you've come to the right place. As experts in the field, we at Labshares know a thing or two about navigating the opportunities
Labshares News
December 9, 2021
Bulfinch Leases 40,000 Square Feet to Labshares
BOSTON & NEWTON, Mass.--(BUSINESS WIRE)--The Bulfinch Companies, Inc. (Bulfinch), a commercial real estate and investment firm, and Labshares Newton today announced the expansion of the life science and biotech co-working incubator at Chapel Bridge..
Labshares News